Entrada Therapeutics is expected to report Q3 2026 results on November 5, with analysts forecasting a consensus revenue of $2.13 million and an EPS loss of $0.98, while the stock currently trades at approximately $4.58 against an average analyst price target of $17.75.
The primary story for investors is the clinical development progress of the company’s lead Duchenne muscular dystrophy (DMD) candidates, ENTR-601-44 and ENTR-601-45.
Recent positive topline data from early-stage cohorts and a favorable safety review for higher-dose testing have provided momentum. Investors are now awaiting updates on trial advancements and management’s latest projections regarding the company’s cash runway, which was previously estimated to last through Q3 2027.